Compare Stocks: ANAB, CGON, PTCT, and ORKA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$45.95 -0.6%	$54.41	$20.18 ▼ $72.36	$1.37B	0.76	691,598 shs	495,168 shs
CGON CG Oncology	$63.82 +0.9%	$73.49	$35.80 ▼ $80.97	$5.66B	0.28	1.10 million shs	516,484 shs
ORKA Oruka Therapeutics	$82.11 +6.3%	$94.86	$24.31 ▼ $115.51	$5.44B	-0.37	1.10 million shs	1.21 million shs
PTCT PTC Therapeutics	$64.70 +3.4%	$68.43	$61.23 ▼ $90.87	$5.40B	0.49	1.37 million shs	1.17 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+1.23%	-4.98%	-18.36%	-30.40%	+45.18%
CGON CG Oncology	+1.41%	-7.45%	-13.81%	-15.92%	+55.39%
ORKA Oruka Therapeutics	-2.79%	-7.36%	-18.06%	-10.96%	+241.80%
PTCT PTC Therapeutics	-1.06%	-2.45%	-9.08%	-26.27%	-2.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$45.95 -0.6%	$54.41	$20.18 ▼ $72.36	$1.37B	0.76	691,598 shs	495,168 shs
CGON CG Oncology	$63.82 +0.9%	$73.49	$35.80 ▼ $80.97	$5.66B	0.28	1.10 million shs	516,484 shs
ORKA Oruka Therapeutics	$82.11 +6.3%	$94.86	$24.31 ▼ $115.51	$5.44B	-0.37	1.10 million shs	1.21 million shs
PTCT PTC Therapeutics	$64.70 +3.4%	$68.43	$61.23 ▼ $90.87	$5.40B	0.49	1.37 million shs	1.17 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+1.23%	-4.98%	-18.36%	-30.40%	+45.18%
CGON CG Oncology	+1.41%	-7.45%	-13.81%	-15.92%	+55.39%
ORKA Oruka Therapeutics	-2.79%	-7.36%	-18.06%	-10.96%	+241.80%
PTCT PTC Therapeutics	-1.06%	-2.45%	-9.08%	-26.27%	-2.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.71	Moderate Buy	$77.79	69.28% Upside
CGON CG Oncology	2.70	Moderate Buy	$87.50	37.10% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$128.91	57.00% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$98.25	51.85% Upside

Current Analyst Ratings Breakdown

Latest ANAB, CGON, PTCT, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
10/7/2026	ORKA Oruka Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
10/7/2026	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$85.00 ➝ $75.00
9/30/2026	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$70.00 ➝ $60.00
9/24/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/24/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00
9/24/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/23/2026	ANAB AnaptysBio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$90.00 ➝ $81.00
9/22/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
9/22/2026	ANAB AnaptysBio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/22/2026	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$130.00 ➝ $137.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$232.39M	5.91	N/A	N/A	$1.34 per share	34.29
CGON CG Oncology	$6.23M	908.32	N/A	N/A	$9.33 per share	6.84
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A
PTCT PTC Therapeutics	$1.73B	3.12	$8.99 per share	7.20	($2.56) per share	-25.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	$5.37	8.56	18.99	N/A	82.37%	112.00%	2.20%	11/3/2026 (Estimated)
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	31.41	1.95	-3.80%	N/A	-1.32%	11/3/2026 (Estimated)

Latest ANAB, CGON, PTCT, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	ANAB AnaptysBio	-$1.84	N/A	N/A	N/A	$25.56 million	N/A
11/3/2026	Q3 2026	PTCT PTC Therapeutics	$0.2735	N/A	N/A	N/A	$303.94 million	N/A
9/21/2026	Q2 2026	ANAB AnaptysBio	-$0.4650	$5.11	+$5.5750	$5.11	$14.06 million	$27.49 million
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
CGON CG Oncology	N/A	22.22	22.20
ORKA Oruka Therapeutics	N/A	38.51	38.51
PTCT PTC Therapeutics	N/A	3.39	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
CGON CG Oncology	26.56%
ORKA Oruka Therapeutics	56.44%
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
CGON CG Oncology	4.80%
ORKA Oruka Therapeutics	23.49%
PTCT PTC Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	104	29.90 million	20.48 million	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	N/A
PTCT PTC Therapeutics	991	83.46 million	79.04 million	Optionable

ANAB, CGON, PTCT, and ORKA Headlines

Recent News About These Companies

PTC Therapeutics (NASDAQ:PTCT) Director Sells 2,500 Shares of Company Stock

35 minutes ago | marketbeat.com

RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating

October 8 at 6:37 PM | marketscreener.comM

PTC Therapeutics (NASDAQ:PTCT) VP Sells 435 Shares of Company Stock

October 8 at 6:37 AM | insidertrades.com

Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock

October 7 at 7:22 PM | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 Shares

October 7 at 7:07 PM | marketbeat.com

PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says

October 7 at 12:01 PM | marketscreener.comM

Cantor raises target for PTC Therapeutics stock to USD 137.00

October 7 at 1:55 AM | ad-hoc-news.deA

PTC Therapeutics (NASDAQ:PTCT) Director Glenn Md Phd Steele, Jr. Sells 12,000 Shares of Company Stock

October 3, 2026 | americanbankingnews.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells 12,000 Shares of Stock

October 3, 2026 | insidertrades.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells $781,920.00 in Stock

October 2, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 4.7% - Here's What Happened

September 28, 2026 | marketbeat.com

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 25, 2026 | prnewswire.com

PTC Therapeutics, Inc.: PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 22, 2026 | finanznachrichten.de

PTC Therapeutics Acquires Sangamo's Fabry Gene Therapy ST-920; Expects BLA Completion In Q4

September 22, 2026 | rttnews.com

Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00

September 22, 2026 | marketbeat.com

PTC Therapeutics acquires Fabry disease gene therapy from Sangamo

September 21, 2026 | streetinsider.com

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 21, 2026 | prnewswire.com

PTC Therapeutics (PTCT) Could Be 36% Undervalued Following Pipeline Progress

September 20, 2026 | finance.yahoo.com

PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 10,000 Shares

September 19, 2026 | insidertrades.com

Bank of America Corp DE Takes $118.46 Million Position in PTC Therapeutics, Inc. $PTCT

September 19, 2026 | marketbeat.com

Wall Street Zen Upgrades PTC Therapeutics (NASDAQ:PTCT) to "Strong-Buy"

September 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, CGON, PTCT, and ORKA Company Descriptions

AnaptysBio NASDAQ:ANAB

$45.95 -0.26 (-0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$45.96 +0.01 (+0.02%)

As of 07:30 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

CG Oncology NASDAQ:CGON

$63.82 +0.56 (+0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$63.83 +0.01 (+0.02%)

As of 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Oruka Therapeutics NASDAQ:ORKA

$82.11 +4.83 (+6.25%)

Closing price 04:00 PM Eastern

Extended Trading

$82.18 +0.08 (+0.09%)

As of 07:30 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

PTC Therapeutics NASDAQ:PTCT

$64.70 +2.14 (+3.42%)

Closing price 04:00 PM Eastern

Extended Trading

$64.68 -0.03 (-0.04%)

As of 07:30 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANAB, CGON, PTCT, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANAB, CGON, PTCT, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANAB, CGON, PTCT, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, CGON, PTCT, and ORKA Company Descriptions

AnaptysBio NASDAQ:ANAB

CG Oncology NASDAQ:CGON

Oruka Therapeutics NASDAQ:ORKA

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANAB, CGON, PTCT, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANAB, CGON, PTCT, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANAB, CGON, PTCT, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, CGON, PTCT, and ORKA Company Descriptions

AnaptysBio NASDAQ:ANAB

CG Oncology NASDAQ:CGON

Oruka Therapeutics NASDAQ:ORKA

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools